Current strategies for the prevention and treatment of disseminated Mycobacterium avium complex infection in patients with AIDS

Pharmacotherapy

Volumn 18, Issue 4, 1998, Pages 738-747

  Wright, Julie ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ETHAMBUTOL; INDINAVIR; NELFINAVIR; RIFABUTIN; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LIFE EXPECTANCY; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; OPPORTUNISTIC INFECTION; PROPHYLAXIS; RASH; REVIEW; TREATMENT FAILURE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MACROLIDES; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION;

EID: 0031823851     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Horsburgh CR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1332-8.
2. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992;165:1082-5.
3. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996;124:633-42.
4. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1099-1106.
5. Sinicco A, Fora R, Raiteri R, et al. Is the clinical course of HIV-1 changing? Cohort study. BMJ 1997;314:1232-7.
6. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
7. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
8. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337: 725-33.
9. Husson RN, Ross LA, Sandelli S, et al. Orally administered clarithromycin for the treatment of systemic Mycobacterium avium complex infection in children with acquired immunodeficiency syndrome. J Pediatrics 1994;124:807-14.
10. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N EnglJ Med 1996;335:377-83.
11. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994;121:905-11.
12. Ward T, Rimland D, Huycke M, Kauffman C, and the VA HIV Consortium Study Group. Randomized, open label trial of azithromycin plus ethambutol versus clarithromycin plus ethambutol therapy of MAC bacteremia in AIDS [abstr]. Presented at the 34th annual meeting of the Infectious Disease Society of America, New Orleans, September 18-20, 1996.
13. Centers for Disease Control and Prevention. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1997;46(no. RR-12):12-13.
14. Jacobson MA. Mycobacterium avium complex (1997 February). In: Cohen PT, Sande MA, Volberding PA, eds. The AIDS knowledge base, 3rd ed. [online]. Available from: URL: http://hivinsite.ucsf.edu/akb/1997/06mac/index.html.
15. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-5.
16. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21:Sl-43.
17. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-33.
18. Moore RD, Chaisson RE. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS 1995;9:1337-42.
19. Mertl SL. The role of clarithromycin in the prophylaxis of disseminated Mycobacterium avium-intracellulare infection in patients with AIDS. Pharmacotherapy 1996;16:393-400.
20. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-91.
21. Benson CA, Cohn D, Williams P, et al. A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin (CLA) versus rifabutin (RBT) versus CLA+RBT for prevention of Mycobacterium avium complex disease in HIV+ patients with CD4 counts < 100 cells/L [abstr]. Presented at the 3rd conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28-February 1, 1996.
22. Oldfield EC, Dickinson G, Chung R, et al. Once weekly azithromycin for the prevention of Mycobacterium avium complex (MAC) infection in AIDS patients [abstr]. Presented at the 3rd conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28-February 1, 1996.
23. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.
24. Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin and rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171:747-50.
25. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685-93.
26. Agouron Pharmaceuticals. Viracept (nelfinavir mesylate) tablets product monograph. La Jolla, CA;1997.
27. Merck & Co. Crixivan (indinavir sulfate) capsules product monograph. West Point, PA;1997.
28. Schlossberg D. Azithromycin and clarithromycin. Med Clin North Am 1995;79:803-15.
29. Abbott Laboratories. Biaxin (clarithromycin) tablets product monograph. North Chicago, IL;1997.
30. Abbott Laboratories. Norvir (ritonavir) capsules product monograph. North Chicago, IL;1997.
31. Pfizer Labs. Zithromax (azithromycin) capsules product monograph. New York, NY;1996.
32. Roche Pharmaceuticals. Fortovase (saquinavir) soft gelatin capsules product monograph. Nutley, NJ;1997.
33. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997;127:289-93.
34. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996;30:919-25.
35. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997;337:441-6.
36. Bauernfeind A, Jungwirth R, Eberlein E. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection 1995;23:316-21.
37. Centers for Disease Control and Prevention. Recommendations on prophylaxis and therapy for disseminated Mycobaterium avium complex for adults and adolescents infected with human immunodeficiency virus. MMWR 1993;42(RR-9):17-20.
38. Kemper CA, Meng TC, Nussbaum J, et al. Treatment of Mycobacterium avium complex in AIDS with a four-drug oral regimen. Ann Intern Med 1992;116:466-72.
39. Kemper CA, Havlir D, Haghighat D, et al. The individual microbiologic effect of three anitmycobacterial agents, clofazimine, ethambutol, and rifampin on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis 1994;170:157-64.
40. Sullam PM, Gordin FM, Wynne BA, et al. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. Clin Infect Dis 1994;19:84-6.
41. Ives DV, Davis RB, Currier JS. Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. AIDS 1995;9:261-6.
42. National Institute of Allergy and Infectious Diseases. Important therapeutic information on the dosing of clarithromycin for the treatment of disseminated Mycobacterium avium complex (DMAC) infection in HIV-infected patients. A note to physicians. Bethesda, MD: National Institutes of Health, 1996.
43. Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997;1:311-17.
44. Dube MP, Sattler FR, Torriani FJ, et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J Infect Dis 1997;176:1225-32.